Irbesartan Jubilant (Irbesartan)

Irbesartan blocks the angiotensin II type 1 (AT1) receptors, preventing angiotensin II from causing vasoconstriction and aldosterone release. This results in relaxed blood vessels, reduced sodium and water retention, and lower systemic vascular resistance, which together lower blood pressure.

The appropriate dose of Irbesartan Jubilant is determined by the prescribing healthcare professional based on the patient’s blood‑pressure readings, renal function, and overall clinical profile. Dosage adjustments are made according to individual response and tolerability.

The safety of Irbesartan in pregnancy is not established and it is generally contraindicated in the second and third trimesters because of potential fetal toxicity. Limited data exist for breastfeeding; therefore, a risk‑benefit assessment by the clinician is required.

To place an order, submit an enquiry on the Irbesartan Jubilant product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Irbesartan belongs to the ARB class, offering blood‑pressure control similar to ACE inhibitors but with a lower incidence of cough and angioedema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle, providing an alternative mechanism for patients who need combination therapy.

Store Irbesartan Jubilant at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiration date printed on the label.

Irbesartan Jubilant is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include angioedema, severe hyperkalemia, and acute renal failure. Patients should seek immediate medical attention if they experience swelling of the face, lips or throat, unexplained muscle weakness, or a sudden decline in kidney function.

Irbesartan is contraindicated in patients with known hypersensitivity to the drug or any ARB, in those with severe hepatic impairment, and in pregnant women during the second and third trimesters. Caution is also advised for individuals with baseline hyperkalemia or severe renal impairment.